| |
 |
 |
How a drug is taken up and processed by the body will determine whether or not it will be effective. At Cyprotex, detailed profiles of potential drugs are generated to understand how they are absorbed, distributed, metabolised and excreted by the body and whether they have the potential to elicit undesirable toxic effects. Collectively known as ADME/toxicity profiles, this information is critical to drug researchers as they select and optimize new compounds during the drug discovery process.
Cyprotex's Cloe® Technologies
Cyprotex's lead optimization engine (Cloe®) is a novel combination of technologies, modelling tools and expertise that can be used by Pharmaceutical and Biotechnology companies to alleviate the problem of inappropriate pharmacokinetics, one of the major causes of attrition in drug discovery and development.
Cloe® enables our partners to improve the overall productivity of their research processes in three key ways:
- Achieve a higher overall success rate through early selection
of the best compounds based on prediction of their in vivo
pharmacokinetics.
- Improve productivity by eliminating failures early and concentrating development time on successful candidates.
- Reap the financial rewards associated with reducing the number of clinical trial failures due to poor pharmacokinetics or unforeseen drug-drug interactions.
Cyprotex is able to achieve this by applying computational
prediction (Cloe® PK) and high capacity experimental screening
(Cloe® Screen) early in the drug discovery process when a large
number of potential drugs are being evaluated.
|
|
Home |
About Us |
Investor Relations |
Products & Services |
Science & Technology |
People |
News & Events |
Contact Us
Overview |
Message from CEO |
Mission statement and strategy
